JP2002542296A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002542296A5 JP2002542296A5 JP2000613446A JP2000613446A JP2002542296A5 JP 2002542296 A5 JP2002542296 A5 JP 2002542296A5 JP 2000613446 A JP2000613446 A JP 2000613446A JP 2000613446 A JP2000613446 A JP 2000613446A JP 2002542296 A5 JP2002542296 A5 JP 2002542296A5
- Authority
- JP
- Japan
- Prior art keywords
- agent
- use according
- hematocrit
- erythropoietin
- cisplatin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 102000003951 Erythropoietin Human genes 0.000 description 5
- 108090000394 Erythropoietin Proteins 0.000 description 5
- 229960004316 cisplatin Drugs 0.000 description 5
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 5
- 229940105423 erythropoietin Drugs 0.000 description 5
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical group [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229960004562 carboplatin Drugs 0.000 description 2
- 190000008236 carboplatin Chemical compound 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/300,124 | 1999-04-27 | ||
| US09/300,124 US6171620B1 (en) | 1999-04-27 | 1999-04-27 | Method of enhancing the efficacy of anti-tumor agents |
| PCT/US2000/011000 WO2000064455A1 (en) | 1999-04-27 | 2000-04-24 | Method of enhancing the efficacy of anti-tumor agents |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002542296A JP2002542296A (ja) | 2002-12-10 |
| JP2002542296A5 true JP2002542296A5 (https=) | 2007-06-28 |
Family
ID=23157813
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000613446A Pending JP2002542296A (ja) | 1999-04-27 | 2000-04-24 | 抗腫瘍剤の効力を増大させる方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6171620B1 (https=) |
| EP (1) | EP1212068A4 (https=) |
| JP (1) | JP2002542296A (https=) |
| KR (1) | KR100693796B1 (https=) |
| CN (1) | CN1188137C (https=) |
| AU (1) | AU781301B2 (https=) |
| BG (1) | BG64940B1 (https=) |
| BR (1) | BR0010082A (https=) |
| CA (1) | CA2368618C (https=) |
| HU (1) | HUP0200840A3 (https=) |
| IL (1) | IL146012A0 (https=) |
| MX (1) | MXPA01010899A (https=) |
| NO (1) | NO20015227L (https=) |
| NZ (1) | NZ514521A (https=) |
| PL (1) | PL350918A1 (https=) |
| RU (1) | RU2271829C2 (https=) |
| WO (1) | WO2000064455A1 (https=) |
| ZA (1) | ZA200108012B (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003531179A (ja) | 2000-04-26 | 2003-10-21 | クイーンズ ユニバーシティ アット キングストン | 悪性細胞表現型に対し一酸化窒素模倣体を使用する処方および方法 |
| US20050142217A1 (en) * | 2000-04-26 | 2005-06-30 | Adams Michael A. | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| US7678391B2 (en) * | 2000-04-26 | 2010-03-16 | Queen's University At Kingston | Formulations and methods of using nitric oxide mimetics against a malignant cell phenotype |
| DE60332358D1 (de) * | 2002-09-09 | 2010-06-10 | Hanall Pharmaceutical Co Ltd | Protease-resistente modifizierte interferon alpha polypeptide |
| HRP20150037T4 (hr) | 2003-04-08 | 2022-09-02 | Progenics Pharmaceuticals, Inc. | Farmaceutske formulacije koje sadrže metilnaltrekson |
| DE10361813A1 (de) * | 2003-12-30 | 2005-09-08 | Bionethos Holding Gmbh | Verfahren zur Regeneration von Gewebe |
| US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
| ES2714198T3 (es) * | 2005-03-07 | 2019-05-27 | Univ Chicago | Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales |
| US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
| AR057035A1 (es) | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS |
| AR057325A1 (es) | 2005-05-25 | 2007-11-28 | Progenics Pharm Inc | Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos |
| TWI489984B (zh) | 2006-08-04 | 2015-07-01 | Wyeth Corp | 用於非經腸道傳輸化合物之配方及其用途 |
| CN101678079B (zh) | 2006-11-28 | 2013-12-25 | 韩诺生物制约株式会社 | 修饰的促红细胞生成素多肽及其治疗用途 |
| MX2009010550A (es) | 2007-03-29 | 2009-12-14 | Progenics Pharm Inc | Formas de cristal de bromuro de (r)-n-metilnaltrexona y uso de las mismas. |
| SI2565195T1 (sl) | 2007-03-29 | 2015-09-30 | Wyeth Llc | Periferalni opioidni receptorji in antagonisti in njih uporaba |
| CL2008000905A1 (es) | 2007-03-29 | 2008-08-22 | Progenics Pharm Inc | Compuestos derivados de morfina, antagonistas del receptor opioide periferico; metodo de preparacion; composicion farmaceutica; y uso para reducir los efectos de la actividad opioide endogena. |
| EP2240489A1 (en) | 2008-02-06 | 2010-10-20 | Progenics Pharmaceuticals, Inc. | Preparation and use of (r),(r)-2,2'-bis-methylnaltrexone |
| EP2278966B1 (en) | 2008-03-21 | 2019-10-09 | The University of Chicago | Treatment with opioid antagonists and mtor inhibitors |
| CA2723621A1 (en) * | 2008-05-15 | 2009-11-19 | Edison Pharmaceuticals, Inc | Treatment of hearing and balance impairments using compounds having erythropoietin activity |
| CA2676881C (en) | 2008-09-30 | 2017-04-25 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
| PL230756B1 (pl) * | 2015-09-11 | 2018-12-31 | Univ Medyczny W Bialymstoku | Erytropoetyna oraz inhibitor kinazy Brutona w postaci 2- cyjan o-N-( 2,5-dibromofenylo)- 3-hydroksy-2- butenamidu do zastosowania jako lek oraz ich zastosowanie do wytwarzania leku do terapii nowotworu |
| WO2019083023A1 (ja) * | 2017-10-26 | 2019-05-02 | 国立大学法人筑波大学 | 癌の治療に使用するための組成物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745099A (en) * | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| JP2632014B2 (ja) * | 1988-03-03 | 1997-07-16 | 中外製薬株式会社 | 骨髄機能障害性貧血治療剤 |
| RU2111750C1 (ru) * | 1995-02-23 | 1998-05-27 | Институт элементоорганических соединений РАН | Модификатор для противоопухолевой терапии |
| JPH1067678A (ja) * | 1996-06-20 | 1998-03-10 | Chugai Pharmaceut Co Ltd | 肝疾患治療用医薬組成物 |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
-
1999
- 1999-04-27 US US09/300,124 patent/US6171620B1/en not_active Expired - Fee Related
-
2000
- 2000-04-24 JP JP2000613446A patent/JP2002542296A/ja active Pending
- 2000-04-24 MX MXPA01010899A patent/MXPA01010899A/es active IP Right Grant
- 2000-04-24 IL IL14601200A patent/IL146012A0/xx unknown
- 2000-04-24 PL PL00350918A patent/PL350918A1/xx not_active Application Discontinuation
- 2000-04-24 WO PCT/US2000/011000 patent/WO2000064455A1/en not_active Ceased
- 2000-04-24 EP EP00926315A patent/EP1212068A4/en not_active Withdrawn
- 2000-04-24 HU HU0200840A patent/HUP0200840A3/hu unknown
- 2000-04-24 BR BR0010082-0A patent/BR0010082A/pt not_active Application Discontinuation
- 2000-04-24 CA CA2368618A patent/CA2368618C/en not_active Expired - Fee Related
- 2000-04-24 CN CNB008065659A patent/CN1188137C/zh not_active Expired - Fee Related
- 2000-04-24 KR KR1020017012929A patent/KR100693796B1/ko not_active Expired - Fee Related
- 2000-04-24 RU RU2001131894/14A patent/RU2271829C2/ru not_active IP Right Cessation
- 2000-04-24 NZ NZ514521A patent/NZ514521A/en not_active IP Right Cessation
- 2000-04-24 AU AU44863/00A patent/AU781301B2/en not_active Ceased
- 2000-12-19 US US09/740,501 patent/US6426094B2/en not_active Expired - Fee Related
-
2001
- 2001-09-28 ZA ZA200108012A patent/ZA200108012B/xx unknown
- 2001-10-25 NO NO20015227A patent/NO20015227L/no not_active Application Discontinuation
- 2001-10-26 BG BG106057A patent/BG64940B1/bg unknown
-
2002
- 2002-07-26 US US10/206,533 patent/US6620779B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002542296A5 (https=) | ||
| BR0207378A (pt) | Tratamento de câncer | |
| AR022974A1 (es) | Una preparacion de cilostazol y un proceso para mejorar la absorcion de una droga levemente soluble. | |
| NZ621449A (en) | Treatment with anti-vegf antibodies | |
| IL179714A (en) | Pharmaceutical preparation containing a history of 2-biphenyl-4-ram-3,2-dehydro-1h-quinazoline-4-on and its use in the preparation of cancer drugs and blood vessel formation | |
| JP2002506648A5 (https=) | ||
| WO2003013541A8 (en) | 4-amino-6-phenyl-pyrrolo[2,3-d]pyrimidine derivatives | |
| DK1196146T3 (da) | Pulverpartikler med glat overflade til anvendelse i inhalationsterapi | |
| JP2004517472A5 (https=) | ||
| DE60203260D1 (de) | Pharmazeutische mischung gegen krebs, die ein 4-chinazolinamin in kombination mit paclitaxel, carboplatin or vinorelbine enthält | |
| WO2001066123A3 (en) | Composition consisting of phy906 and chemotherapeutic agents | |
| DE60143393D1 (de) | Modifizierte formen pharmazeutisch aktiver agenzien und verwendungen dafür | |
| JP2006514116A5 (https=) | ||
| WO2002056835A3 (en) | Anticancer treatment using triptolide prodrugs | |
| AUPQ879500A0 (en) | Hyaluronan as cytotoxic agent, drug presensitizer and chemo-sensitizer in the treatment of disease | |
| MXPA03008423A (es) | Agonistas del receptor nicotinico para el tratamiento de enfermedades inflamatorias. | |
| WO2001062235A3 (en) | A composition comprising camptothecin and a pyrimidine derivative for the treatment of cancer | |
| UA72927C2 (uk) | Композиція для лікування печінково-клітинного раку, що містить доцетаксель | |
| JP2003526667A5 (https=) | ||
| ATE417608T1 (de) | Arzneizusammensetzungen enthaltend modafinilverbindungen | |
| WO2007149586A3 (en) | Anti-c35 antibodies for treating cancer | |
| CA2310950A1 (en) | An efficacious dosage regiment of galantamine that reduces side effects | |
| WO2003007914A3 (en) | Biocompatible polymer containing composition for treatment of prostate cancers | |
| JP2009516719A5 (https=) | ||
| AU4789099A (en) | Therapeutic composition based on flavonoids for use in the treatment of tumours with cytotoxic agents |